Clinical trial
The Effect Of AVANDIA On The Late Asthmatic Response
NCT00318630 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00318630 |
|---|---|
| Title | The Effect Of AVANDIA On The Late Asthmatic Response |
| Official title | A Randomised Double-blind Two-period Crossover Study to Investigate the Effect of Treatment With Repeat Doses of a PPAR Gamma Agonist on the Allergen-induced Late Asthmatic Response in Subjects With Mild Asthma Compared With Repeat Doses of Placebo |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Rosiglitazone, Placebo |
| Enrollment | 26 |
| Start date | Jul 22, 2005 |
| Primary completion | Jun 30, 2006 |
| Completion | Jun 30, 2006 |
| First posted | Apr 27, 2006 |
| Last update posted | Sep 25, 2017 |
| Countries | New Zealand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: